Cargando…

PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

Detalles Bibliográficos
Autores principales:	Abdul-Hay, Maher, Dinardo, Courtney, Chan, Onyee, Narayan, Rupa, Issa, Ghayas, Michaelson, Jennifer, Baeuerle, Patrick, Meetze, Kristan, Janik, John, Shapiro, Irina, Inumerable, Judy, Jones, Jeffery, Sallman, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430354/ http://dx.doi.org/10.1097/01.HS9.0000974228.65087.81

Ejemplares similares

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
por: Meetze, Kristan, et al.
Publicado: (2023)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice
por: Annesley, Colleen E., et al.
Publicado: (2018)

PP2A: The Achilles Heal in MDS with 5q Deletion
por: Sallman, David A., et al.
Publicado: (2014)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Loss of MiR-155 Sensitizes FLT3-ITD(+)AML to Chemotherapy and FLT3 Inhibitors via Glycolysis Blocking by Targeting PIK3R1
por: Wang, Lingyan, et al.
Publicado: (2023)

Cs(0.49)NbPS(6)
por: Lee, Eunsil, et al.
Publicado: (2010)

CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients
por: Uckun, Fatih M., et al.
Publicado: (2021)

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
por: Perl, Alexander E., et al.
Publicado: (2022)

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3(mut) AML
por: Terao, Toshiki, et al.
Publicado: (2022)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
por: Soldati, Chiara, et al.
Publicado: (2021)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

Age-related epigenetic drift in the pathogenesis of MDS and AML
por: Maegawa, Shinji, et al.
Publicado: (2014)

Data on characterizing the gene expression patterns of neuronal ceroid lipofuscinosis genes: CLN1, CLN2, CLN3, CLN5 and their association to interneuron and neurotransmission markers: Parvalbumin and Somatostatin
por: Minye, Helena M., et al.
Publicado: (2016)

Mathias Mayor (1775–1847)
por: Librach, I. M.
Publicado: (1970)

P01-049 – Assessment of vascular function in systemic JIA
por: Sozeri, B, et al.
Publicado: (2013)

P049. Migraine influence on female reproductive life and motherhood
por: Fuccaro, Matteo, et al.
Publicado: (2015)

AB049. The importance of Uro-Andro-check in sexual medicine
por: Soebadi, Doddy M.
Publicado: (2015)

AB049. Application of postoperative follow-up system for varicocele
por: Wang, Lei, et al.
Publicado: (2018)

SAT-049 Growth Hormone Treatment in Mexican Turner's Syndrome
por: Bonilla, Paola, et al.
Publicado: (2019)

A comparative study of the degradation of yeast cyclins Cln1 and Cln2
por: Quilis, Inma, et al.
Publicado: (2016)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
por: Jawad, Majd, et al.
Publicado: (2022)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

American Society of Hematology 2020 Podcast Collection: MDS and AML
por: Almeida, António
Publicado: (2021)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
por: Johnson, Lisa, et al.
Publicado: (2023)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

PSAT049 A Case of Hypercalcemia as the First Presentation of Addison's Disease
por: Horani, Mohamad, et al.
Publicado: (2022)

Adriaan Isebree Moens (1847-1891)
por: Dow, Philip
Publicado: (1940)

The London and Provincial Medical Directory, 1847
Publicado: (1847)

The Norfolk and Norwich Hospital, 1771-1847
Publicado: (1916)

Erratum in Our Number for June 1847
Publicado: (1849)

Notes on the Epidemic Fever of 1847-48
por: Robertson, William
Publicado: (1848)

Cannot write session to /tmp/vufind_sessions/sess_pmlvotjnmcve01gijuooer9isp